BEAM

23.93

1.77% -0.43

Dopo l'orario di chiusura: 23.94 0.01 +0.04%

Beam Therapeutics Inc (BEAM)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BEAM Giù? Forum Previsione

Precedente Chiudi:

$24.36

Aprire:

$21.62

Volume 24 ore:

2.29M

Relative Volume:

2.75

Capitalizzazione di mercato:

$1.97B

Reddito:

$352.57M

Utile/perdita netta:

$-143.01M

Rapporto P/E:

-5.306

EPS:

-4.51

Flusso di cassa netto:

$-153.40M

1 W Prestazione:

+7.94%

1M Prestazione:

+2.22%

6M Prestazione:

+3.46%

1 anno Prestazione:

-2.29%

Intervallo 1D:

$21.46

$24.79

Intervallo di 1 settimana:

$21.46

$24.95

Portata 52W:

$18.85

$49.50

Beam Therapeutics Inc Stock (BEAM) Company Profile

Nome

Beam Therapeutics Inc

Settore

Healthcare (1182)

Industria

Biotechnology (671)

Telefono

857-327-8775

Indirizzo

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Dipendente

461

Cinguettio

Prossima data di guadagno

2024-11-05

Ultimi documenti SEC

BEAM's Discussions on Twitter

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-01-29	Aggiornamento	JP Morgan	Neutral → Overweight
2023-12-15	Downgrade	BofA Securities	Buy → Neutral
2023-12-08	Downgrade	Jefferies	Buy → Hold
2023-10-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2023-10-20	Downgrade	Leerink Partners	Outperform → Market Perform
2023-03-21	Iniziato	Bernstein	Mkt Perform
2023-02-01	Iniziato	Cantor Fitzgerald	Overweight
2022-12-20	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2022-12-13	Iniziato	Citigroup	Buy
2022-06-17	Iniziato	BMO Capital Markets	Market Perform
2022-04-28	Iniziato	Credit Suisse	Neutral
2022-01-05	Iniziato	Guggenheim	Buy
2021-10-19	Iniziato	SVB Leerink	Outperform
2021-09-24	Ripresa	Stifel	Buy
2021-09-10	Iniziato	BofA Securities	Buy
2021-05-11	Iniziato	Redburn	Buy
2021-05-04	Iniziato	RBC Capital Mkts	Sector Perform
2021-03-01	Downgrade	Barclays	Overweight → Equal Weight
2021-02-16	Iniziato	Wells Fargo	Overweight
2021-01-29	Downgrade	JP Morgan	Overweight → Neutral
2021-01-06	Iniziato	Stifel	Hold
2020-08-05	Iniziato	William Blair	Outperform
2020-03-02	Iniziato	Barclays	Overweight
2020-03-02	Iniziato	JP Morgan	Overweight
2020-03-02	Iniziato	Jefferies	Buy
2020-03-02	Iniziato	Wedbush	Outperform

Mostra tutto

Beam Therapeutics Inc Borsa (BEAM) Ultime notizie

05:24 AM

Beam Is Laser-Focused On ASH As It Reports Promising Sickle Cell Data, And A Death - Scrip

05:24 AM

04:55 AM

SCD phase I/II death shines Beam on ‘very real’ busulfan risk - BioWorld Online

04:55 AM

04:17 AM

Beam’s Base-Editing Sickle Cell Therapy Shows Early Promise, But a Fatality Overshadows Results - MedCity News

04:17 AM

03:37 AM

Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial - Yahoo Finance

03:37 AM

03:28 AM

JPMorgan maintains $48 target on Beam Therapeutics stock - Investing.com

03:28 AM

Stifel maintains $69 target on Beam Therapeutics stock - Investing.com

03:28 AM

02:47 AM

Beam Therapeutics' early base editing clinical data overshadowed by patient death - The Business Journals

02:47 AM

11:39 AM

Beam Therapeutics (NASDAQ:BEAM) Shares Gap Down Following Weak Earnings - MarketBeat

11:39 AM

11:21 AM

Beam Therapeutics sustains Outperform stock rating on clinical data - Investing.com

11:21 AM

10:55 AM

Beam Therapeutics (NASDAQ:BEAM) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat

10:55 AM

10:32 AM

Beam Therapeutics sustains Outperform stock rating on clinical data By Investing.com - Investing.com UK

10:32 AM

10:18 AM

Beam Therapeutics' Sickle Cell Treatment Shows Promising Results in First Clinical Trial | BEAM Stock News - StockTitan

09:00 AM

08:26 AM

Beam Therapeutics Inc Reports Q3 2024 EPS of $1.17, Revenue of $14.27 Million, Slightly Missing Estimates - GuruFocus.com

08:26 AM

07:40 AM